🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆ Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆ Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines ◆
Updated 26 Aug 2026 · ClinicalTrials.gov

Clinical Trials in Cambridge

← All UK trials

The most recently updated industry-sponsored clinical trials recruiting across the United Kingdom — searchable by condition, sponsor, phase and city. Refreshed daily from the ClinicalTrials.gov registry.

28
Recruiting now
36
Studies tracked
Cambridge
Selected city
Active Phase 2
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms
Hoffmann-La Roche · started 2015-11-19
📍 Cambridge · London · Manchester
NCT02568267 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
Chronic Graft-versus-host-disease
Incyte Corporation · started 2026-05-20
📍 Birmingham · Cambridge · Glasgow · Leeds · London
NCT07124078 on ClinicalTrials.gov ↗
Recruiting Phase 1
A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)
Alpha 1 Antitrypsin Deficiency
AIRNA Corporation · started 2026-03-17
📍 Cambridge · London · Southampton
NCT07431112 on ClinicalTrials.gov ↗
Active Phase 3
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
Chronic Lymphocytic Leukemia
Acerta Pharma BV · started 2015-06-26
📍 Bournemouth · Cambridge · Leeds · Leicester · London
NCT02475681 on ClinicalTrials.gov ↗
Recruiting Phase 1
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Multiple Sclerosis
AstraZeneca · started 2025-12-09
📍 Cambridge · London
NCT07224373 on ClinicalTrials.gov ↗
Active
A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease
Pompe Disease (Late-onset)
Astellas Gene Therapies · started 2024-02-01
📍 Cambridge · Newcastle upon Tyne · Salford
NCT06150820 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Pitolisant in Patients With Prader-Willi Syndrome
Prader-Willi Syndrome
Harmony Biosciences Management, Inc. · started 2024-05-28
📍 Cambridge · Hull · Dundee · Edinburgh
NCT06366464 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
Diabetes Mellitus, Type 1
Eli Lilly and Company · started 2026-01-12
📍 Birmingham · Cambridge · Cardiff · Glasgow · London
NCT07222137 on ClinicalTrials.gov ↗
Recruiting Phase 3
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
Nuvalent Inc. · started 2025-07-17
📍 Cambridge · Guildford · Hampstead · London · Maidstone
NCT06765109 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Graves' Disease
Immunovant Sciences GmbH · started 2024-12-17
📍 Birmingham · Bristol · Coventry · London · Cambridge
NCT06727604 on ClinicalTrials.gov ↗
Recruiting Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid Tumors, Hematologic Malignancies
Merck Sharp & Dohme LLC · started 2018-08-21
📍 Aberdeen · Cambridge · Edinburgh · Manchester · Sheffield
NCT03486873 on ClinicalTrials.gov ↗
Active Phase 4
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
Asthma
AstraZeneca · started 2019-10-08
📍 Cambridge · Headington · Leicester · Liverpool · London
NCT03953300 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Bladder Cancer
Merck Sharp & Dohme LLC · started 2026-04-23
📍 Cambridge
NCT07419295 on ClinicalTrials.gov ↗
Recruiting Phase 3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Prostate Cancer Metastatic
Merck Sharp & Dohme LLC · started 2023-12-31
📍 Cambridge · Truro · Glasgow · London · Manchester
NCT06136624 on ClinicalTrials.gov ↗
Recruiting Phase 2
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
Lupus Nephritis
Autolus Limited · started 2026-01-16
📍 Birmingham · Bristol · Cambridge · Edinburgh · Glasgow
NCT07053800 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
Cardiovascular Disease
AstraZeneca · started 2025-06-04
📍 Birmingham · Bournemouth · Bridgend · Bristol · Calow
NCT07000357 on ClinicalTrials.gov ↗
Recruiting Phase 2
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
AbbVie · started 2026-01-23
📍 Cambridge · Edinburgh · London · Southampton · Norwich
NCT07230288 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
BeOne Medicines · started 2025-08-27
📍 Cambridge · Dundee · Metropolitan Borough of Wirral
NCT07043400 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Pfizer · started 2025-10-03
📍 Cambridge · London · Edinburgh · Liverpool
NCT06989437 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Endometrial Cancer
Merck Sharp & Dohme LLC · started 2025-05-22
📍 East Sussex · Cambridge · Glasgow · London · Edinburgh
NCT06952504 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
Ulcerative Colitis
AbbVie · started 2025-07-28
📍 Cambridge · Sheffield · Liverpool
NCT07071519 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Merck Sharp & Dohme LLC · started 2023-12-18
📍 Cambridge · Derby · Torquay · Northwood · Truro
NCT06136650 on ClinicalTrials.gov ↗
Active Phase 2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Hepatocellular Carcinoma, Biliary Tract Cancer
AstraZeneca · started 2023-04-24
📍 Cambridge · London · Manchester
NCT05775159 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Merck Sharp & Dohme LLC · started 2025-04-09
📍 Cambridge · Edinburgh · Preston · London · Sutton
NCT06824467 on ClinicalTrials.gov ↗
Recruiting Phase 2
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
Type 1 Diabetes
SAb Biotherapeutics, Inc. · started 2025-11-25
📍 Cambridge · Cardiff · Edinburgh · Liverpool · London
NCT07187531 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Obesity, Overweight
Eli Lilly and Company · started 2024-11-18
📍 Barnsley · Bristol · Cambridge · Dundee · Harrow
NCT06672549 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
Amgen · started 2025-07-16
📍 Cambridge · Edinburgh · Leicester · Newcastle upon Tyne
NCT06570798 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Castration-Resistant Prostatic Cancer, Metastasis
Merck Sharp & Dohme LLC · started 2025-07-03
📍 Cambridge · London
NCT06863272 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Prostate Cancer
AstraZeneca · started 2025-08-06
📍 Aberdeen · Bristol · Cambridge · Edinburgh · Exeter
NCT06952803 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC · started 2021-05-12
📍 Cambridge · Glasgow · London · Newcastle upon Tyne · Sheffield
NCT07218029 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Prostate Cancer, Prostatic Neoplasms
Merck Sharp & Dohme LLC · started 2025-05-13
📍 Cambridge · London · Exeter · Birmingham · Northwood
NCT06925737 on ClinicalTrials.gov ↗
Active Phase 3
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
Tuberous Sclerosis Complex
Novartis Pharmaceuticals · started 2017-08-23
📍 Birmingham · Buckinghamshire · Cambridge · Liverpool · London
NCT02962414 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma
Celgene · started 2022-09-20
📍 Cambridge · Truro · Airdrie · London · Leicester
NCT05519085 on ClinicalTrials.gov ↗
Active Phase 3
Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury
Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
Merz Pharmaceuticals GmbH · started 2019-09-16
📍 Cambridge · Exeter · Liverpool
NCT03992404 on ClinicalTrials.gov ↗
Active
CGM Use in Adults With Type 2 Diabetes on Basal Insulin
Diabetes Mellitus, Type 2
Abbott Diabetes Care · started 2023-07-14
📍 Ashton-under-Lyne · Bath · Birmingham · Cambridge · Darlington
NCT05944432 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Myelodysplastic Syndromes
Takeda · started 2025-05-06
📍 Aberdeen · Rhyl · Leicester · High Heaton · Sunderland
NCT06499285 on ClinicalTrials.gov ↗
No trials match your search.

Browse by city

London · 111 Manchester · 39 Cambridge · 36 Birmingham · 32 Glasgow · 25 Bristol · 23 Edinburgh · 23 Oxford · 22 Sheffield · 21 Newcastle upon Tyne · 20 Leicester · 17 Liverpool · 16 Leeds · 16 Sutton · 13 Truro · 13 Aberdeen · 12

Browse by condition

Chronic Lymphocytic Leukemia · 5 Prostate Cancer · 4 Breast Cancer · 3 Non-small Cell Lung Cancer · 3 Healthy · 3 Ulcerative Colitis · 3 Crohn's Disease · 3 Advanced Solid Tumor · 3 Multiple Myeloma · 3 Neoplasm Metastasis · 3 Heart Failure · 3 Hypertension · 2 Metastatic Colorectal Cancer · 2 Obesity or Overweight · 2 Diabetes Mellitus, Type 2 · 2 Graves' Disease · 2
Cite this page

Priya Life Science (2026). Clinical Trials in the UK Tracker. Available at: https://priyalifescience.com/clinical-trials-uk/city/cambridge (Accessed: 26 August 2026).

Embed this data ↗

Source: ClinicalTrials.gov, U.S. National Library of Medicine — industry-sponsored studies in a recruiting status with at least one UK site, most recently updated first, refreshed daily. This is a curated slice of the registry, not every UK trial; UK studies may also be registered on ISRCTN. Listing here is informational and not medical advice; eligibility is determined by each study team. Patients should discuss participation with their clinician. Compare pay for the teams running these studies in our UK Pharma Salary Guide, or see our Ireland, EU and USA trackers.